Dynamics the parameters of mineral metabolism in hospitalized patients with COVID-19, the impact of etiotropic and pathogenetic therapy

The high prevalence of COVID-19 requires the research progress on the disease pathogenesis. There is a lot of data confirming the association between mineral metabolism and the severity of COVID-19.
AIM: To study the dynamics of mineral metabolism parameters in patients with a confirmed COVID-19 at the time of hospitalization and after discharge, including the impact of etiotropic and pathogenetic therapy on them.
MATERIALS AND METHODS: A single-center study of 106 patients (aged ≥18 years) with clinically or laboratory confirmed diagnosis of COVID-19 was carried out at the Endocrinology Research Centre, Moscow. Baseline biochemical parameters, including serum calcium, phosphorus, albumin, 25(OH)D, parathyroid hormone (PTH), inflammatory markers, and instrumental assessment of COVID-19 severity were performed before specific immunotherapy, as well as on 3rd and 7th days of hospitalization and before discharge. Statistical analysis was performed with Statistica 13 software (StatSoft, USA).
RESULTS: On the first day, hypocalcemia (low albumin-adjusted calcium level) was detected in 40.6% of cases, the prevalence of vitamin D deficiency/insufficiency amounted to 95.3% of cases. At the same time, secondary hyperparathyroidism was identified only in 14.2% of patients. A comparative analysis of mineral metabolism during hospitalization (between 1, 3, 7 days of hospitalization and before discharge) during baricitinib treatment revealed a statistically significant increase in albumin-adjusted calcium by the end of hospitalization (p<0.001, Friedman criterion, Bonferroni correction p0=0.01). A pairwise comparison of subgroups, depending on the therapy, revealed a statistically significantly lower level of albumin-adjusted calcium on 3rd day among patients on baricitinib monotherapy or combined with tocilizumab compared with a subgroup of patients undergoing etiotropic treatment (2.16 [2.13; 2.18] mmol/l vs 2.23 [2.19; 2.28] mmol/l, p=0.002, U-test, Bonferroni correction p0=0.012).
CONCLUSION: Patients with severe coronavirus infection are characterized by a high prevalence of vitamin D deficiency and hypocalcemia. Associations between calcium and saturation as well as the severity of lung lesion characterizes hypocalcemia as an important predictor of severe course and poor outcome in COVID-19. Pathogenetic therapy with baricitinib, including in combination with tocilizumab, contributes to achieve normocalcemia, but further studies are required.

1. V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155-170. doi: https://doi.org/10.1038/s41579-020-00468-6

2. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [cited March 22, 2023]. Available from: https://coronavirus.jhu.edu/map.html

3. Martha JW, Wibowo A, Pranata R. Hypocalcemia is associated with severe COVID-19: A systematic review and metaanalysis. Diabetes Metab Syndr Clin Res Rev. 2021;15(1):337-342. doi: https://doi.org/10.1016/j.dsx.2021.01.003

4. Liu J, Han P, Wu J, et al. Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health. 2020;13(9):1224-1228. doi: https://doi.org/10.1016/j.jiph.2020.05.029

5. Yang C, Ma X, Wu J, et al. Low serum calcium and phosphorus and their clinical performance in detecting COVID‐19 patients. J Med Virol. 2021;93(3):1639-1651. doi: https://doi.org/10.1002/jmv.26515

6. Trapani V, Rosanoff A, Baniasadi S, et al. The relevance of magnesium homeostasis in COVID-19. Eur J Nutr. 2022;61(2):625-636. doi: https://doi.org/10.1007/s00394-021-02704-y

7. Giustina A. Hypovitaminosis D and the endocrine phenotype of COVID-19. Endocrine. 2021;72(1):1-11. doi: https://doi.org/10.1007/s12020-021-02671-8

8. Hashemipour S, Kiani S, Shahsavari P, et al. Hypocalcemia in hospitalized patients with COVID-19: roles of hypovitaminosis D and functional hypoparathyroidism. J Bone Miner Metab. 2022;40(4):663-669. doi: https://doi.org/10.1007/s00774-022-01330-w

9. Vremenny’e metodicheskie rekomendacii Ministerstva zdravooxraneniya Rossijskoj Federacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya 5, 08.04.20. (In Russ.). Available from: https://static-2.rosminzdrav.ru/system/attachments/attaches/000/049/949/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%D0%B2%D0%B5%D1%80%D1%81%D0%B8%D1%8F_5.pdf. 30.04.2023.

10. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care (10-th edition). Diabetes Mellitus. 2021;24(S1):1-235. (In Russ.). doi: https://doi.org/10.14341/DM12802

11. Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. (In Russ.). doi: https://doi.org/10.14341/probl12801

12. Zhou Y, Frey TK, Yang JJ. Viral calciomics: Interplays between Ca2+ and virus. Cell Calcium. 2009;46(1):1-17. doi: https://doi.org/10.1016/j.ceca.2009.05.005

13. Avdeeva VA, Suplotova LA, Pigarova EA, et al. Vitamin D deficiency in Russia: the first results of a registered, non-interventional study of the frequency of vitamin D deficiency and insufficiency in various geographic regions of the country. Problems of Endocrinology. 2021;67(2):84-92. (In Russ.). doi: https://doi.org/10.14341/probl12736

14. Di Filippo L, Allora A, Locatelli M, et al. Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response. Endocrine. 2021;74(2):219-225. doi: https://doi.org/10.1007/s12020-021-02882-z

15. Canaff L, Zhou X, Hendy GN. The proinflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Stat1/3 and Sp1/3. J Biol Chem. 2008;283(20):13586-13600. doi: https://doi.org/10.1074/jbc.M708087200

16. Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens. 2002;11(4):403-410. doi: https://doi.org/10.1097/00041552-200207000-00006

17. Fakhrolmobasheri M, Vakhshoori M, Heidarpour M, et al. Hypophosphatemia in Coronavirus Disease 2019 (COVID-19), complications, and considerations: A systematic review. Biomed Res Int. 2022;2022:1-11. doi: https://doi.org/10.1155/2022/1468786

18. Hashemipour S, Kiani S, Shahsavari P, et al. Contributing factors for calcium changes during hospitalization in COVID-19: A longitudinal study. Int J Endocrinol Metab. 2022;20(2). doi: https://doi.org/10.5812/ijem-122378

19. Minasi A, Andreadi A, Maiorino A, et al. Hypocalcemia is associated with adverse outcomes in patients hospitalized with COVID-19. Endocrine. 2022;79(3):577-586. doi: https://doi.org/10.1007/s12020-022-03239-w

20. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. doi: https://doi.org/10.1016/S0140-6736(20)30304-4